Efficacy of Rostafuroxin in the Treatment of Essential Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

August 31, 2007

Conditions
Essential Hypertension
Interventions
DRUG

Rostafuroxin

1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin

DRUG

Rostafuroxin

1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin

DRUG

Rostafuroxin

1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin

DRUG

Rostafuroxin

1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin

DRUG

Rostafuroxin

1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin

Trial Locations (1)

B-3000

Catholic University of Leuven - Laboratory of Hypertension, Dept. of Molecular and Cardiov. Research - Campus Gasthuisberg, Leuven

All Listed Sponsors
lead

sigma-tau i.f.r. S.p.A.

INDUSTRY

NCT00415038 - Efficacy of Rostafuroxin in the Treatment of Essential Hypertension | Biotech Hunter | Biotech Hunter